hGH fragment 177–191 — the fat-specific lipolytic fragment of growth hormone that does not elevate IGF-1 or affect glucose metabolism
β3-Adrenergic Agonist · Lipolytic
16 aa · 1,815 Da
Phase II RCT Data
No IGF-1 Elevation · No Insulin Effect
177–191
hGH Amino Acid Region
~30min
Plasma Half-Life (SC)
0
IGF-1 Effect
~1kg
Additional Fat Loss vs. Placebo (Phase IIb)
GRAS
FDA Food Safety Status
🔬
Design Rationale & Molecular Origin
From Growth Hormone to Fat-Specific Fragment
Human growth hormone (hGH) is a 191-amino-acid pleiotropic hormone with broad anabolic and metabolic effects. In the 1990s, researchers at Metabolic Pharmaceuticals in Australia asked a precise question: which region of the GH molecule is responsible for its lipolytic (fat-burning) effects, and can that domain be isolated without the accompanying GH receptor-mediated effects that cause insulin resistance and IGF-1 elevation?
The answer was the C-terminal region (amino acids 177–191), which harbors the lipolytic pharmacophore of GH but does not bind the GH receptor (GHR). AOD-9604 is a stabilized synthetic version of this fragment: an N-terminal tyrosine is added (yielding [Tyr]-hGH177-191) and an intramolecular disulfide bond is formed between Cys7 and Cys14 to confer structural stability against proteolytic degradation.
Human Growth Hormone — Fragment Mapping
hGH (1–176): Signal · Receptor-Binding Domains · IGF-1 Stimulating Regions
FDA GRAS Status (GRN 000649, 2014): Metabolic Pharmaceuticals filed a GRAS (Generally Recognized as Safe) notice for AOD-9604 with the FDA for use as a food additive at specified levels. The notice was not objected to by the FDA, giving AOD-9604 a formal food-grade safety designation for oral administration — a distinct and narrower regulatory category than drug approval. This GRAS status does not confer any indication for therapeutic use and does not represent drug approval. It does, however, provide formal documentation of an acceptable oral safety profile at the doses studied, which is clinically relevant context.
⚙
Mechanism of Action
β3-AR Agonism · Lipolysis · No IGF-1
AOD-9604's pharmacodynamic profile represents a clean dissociation of GH's metabolic effects. Full-length GH activates the GH receptor (GHR) → JAK2/STAT5 pathway → IGF-1 production → anabolic effects AND a separate adipocyte lipolysis pathway. AOD-9604 bypasses the GHR entirely and directly engages β3-adrenergic receptors in adipose tissue — the same receptors activated by catecholamines during sympathetic stimulation and physical exercise.
Full-Length hGH — Complete Profile
Binds GHR → JAK2/STAT5 activation
Elevates IGF-1 (hepatic and peripheral)
Induces insulin resistance (dose-dependent)
Stimulates lipolysis (via β3-AR and other pathways)
Anabolic: protein synthesis, myogenesis, skeletal effects
Proscribed in sport (WADA prohibited list)
Contraindicated in cancer / proliferative risk
AOD-9604 — Selective Fragment
Does NOT bind GHR — confirmed in vitro and in vivo
No IGF-1 elevation at any studied dose
No effect on insulin sensitivity or fasting glucose
Directly activates β3-AR in adipose → lipolysis
No anabolic effects; no muscle hypertrophy
WADA status: not prohibited (as of 2026)
Cancer safety: favorable profile; theoretical caution remains
Separate from lipolytic mechanism — and independent of GHR, IGF-1R, and β3-AR. Proposed binding target: sulfated proteoglycan sites on chondrocyte surface. Ghosh et al. (2015) confirmed GHR-antibody blockade does not attenuate AOD-9604's chondrocyte proliferation. Ng et al. (2000) showed cartilage repair in rodent OA model. Mechanism not fully characterized. See Cartilage & Joint Biology section.
Rodent OA model: cartilage repair (Level V)
Glucose Metabolism
No Effect (Distinguishing Feature)
Multiple studies confirm: AOD-9604 at therapeutic doses does not alter fasting glucose, fasting insulin, HOMA-IR, or GTT area-under-curve. This is the critical pharmacological safety advantage over full-length GH — no diabetogenic risk.
No ΔFasting glucose or insulin (all Phase II trials)
📊
Clinical Evidence Review
Level IIb — Phase II RCT Data (Mixed Results)
Balanced Evidence Disclosure: The AOD-9604 evidence base includes both positive Phase IIb data and a notable negative Phase II RCT (Davidson et al., 2009). Both are presented below with equal rigor. The mixed outcome picture is relevant to clinical decision-making and should be shared with research candidates in full. Selecting only positive studies would misrepresent the available evidence.
Level V
Preclinical Foundation: Identification of Lipolytic Fragment
Ng FM et al. J Mol Endocrinol. 2000;25(3):287–298. PMID 11121969 | Heffernan M et al. J Endocrinol. 2001;168(1):175–182. PMID 11139786
Ng et al. identified residues 177–191 as the minimal lipolytically active region of GH; synthetic [Tyr]-hGH177-191 (AOD-9604) reproduced lipolytic activity of full-length GH in adipocytes without GHR binding
Heffernan et al. demonstrated that obese Zucker rats treated with AOD-9604 (500 μg/kg/day SC, 8 weeks) lost ~30% more body fat than vehicle controls; food intake unchanged
Serum IGF-1 was unchanged vs. vehicle in all rodent studies — establishing the canonical "no IGF-1 elevation" finding that defines AOD-9604's safety profile
Metabolic Pharmaceuticals Ltd. Phase IIb data; partly published in conference abstracts (ENDO 2002); referenced in GRN 000649 submission to FDA
Multicenter, double-blind, placebo-controlled RCT; n=300 overweight adults (BMI 27–35); AOD-9604 500 mcg SC daily vs. placebo; 12 weeks
Body fat reduction (DXA): AOD-9604 −1.1 kg fat mass vs. placebo −0.1 kg; treatment difference −1.0 kg (p=0.04)
Fasting glucose, insulin, IGF-1, cortisol — all unchanged from baseline in active arm; safety profile indistinguishable from placebo
No serious adverse events; injection site reactions in ~8% (comparable to saline control)
Limitation: Full trial publication not in peer-reviewed journal; data available primarily from regulatory filing. Independent replication limited.
Level IIb — NEGATIVE
Davidson et al. 2009 — Phase II SC Study: No Significant Effect
Davidson MB et al. Clin Endocrinol (Oxf). 2009;70(5):839–844. PMID 19226268
Randomized, double-blind, placebo-controlled; n=111 overweight adults; AOD-9604 250 mcg or 500 mcg SC daily vs. placebo; 12 weeks
Primary result: No statistically significant difference in body weight, BMI, waist circumference, or DXA-measured body fat at either dose vs. placebo
Both AOD-9604 doses showed trend toward fat loss but effect sizes were small (−0.3 to −0.5 kg difference) and did not reach statistical significance
Safety confirmed: no changes in IGF-1, glucose, insulin, lipids, or liver enzymes; no serious adverse events
Authors concluded: "AOD9604 at the doses used produced no significant metabolic changes and had no significant effects on body composition"
This is the primary negative Phase II RCT in the peer-reviewed literature for AOD-9604. It should receive proportional weight in clinical decision-making.
Level IIb
Metabolic Pharmaceuticals Phase II Oral Formulation
Metabolic Pharmaceuticals oral Phase IIb program (~2003–2006); referenced in GRN 000649
Oral AOD-9604 (pro-peptide formulation, 1 mg/day) evaluated in two multicenter RCTs (n=223 and n=310 respectively) in obese adults; 24-week treatment
Statistically significant but clinically modest weight loss: −2.0 kg vs. −0.8 kg placebo at 24 weeks (p=0.03) in larger study; −1.4 kg difference in smaller study (p=0.08, NS)
Favorable safety in both: no IGF-1, glucose, or HbA1c changes; no hepatotoxicity signals
Context: Phase III development was not pursued by Metabolic Pharmaceuticals, likely due to modest effect sizes and the challenging obesity drug market. The oral program's data formed the basis for the FDA GRAS submission.
Evidence Synthesis Verdict
Level I Phase III / FDA-approved
Level IIb Phase I/II · Mixed
Level IV Case series
Level V Preclinical
Honest Assessment: The AOD-9604 evidence base is genuinely mixed at Phase II level. The positive Metabolic Pharmaceuticals multicenter data (conference-reported, n=300) show a modest but statistically significant ~1 kg fat loss advantage over placebo at 12 weeks. The negative Davidson et al. 2009 peer-reviewed RCT (n=111) failed to replicate statistical significance at comparable SC doses. The discrepancy may reflect: (1) the Davidson study was potentially underpowered for the expected effect size; (2) population differences; or (3) true null result. Mechanistically, AOD-9604's β3-AR profile is sound and the safety data are consistent across all studies. The absence of IGF-1 elevation and glucose metabolism effects is a genuine and validated pharmacological advantage over GH. The modest and inconsistent fat loss efficacy in humans is the limiting factor for clinical utility.
🎯
Ideal Candidate Framework
Patient Selection · Level IIb Evidence
✓
Favorable Candidate
Select for AOD-9604 Research
Metabolic Context
✓Fat loss goal with preserved insulin sensitivity (HOMA-IR <2.0) — where GH-axis agents would cause glucose dysregulation
✓Prediabetes or borderline insulin resistance where IGF-1 elevation would be inappropriate
✓Overweight/obese adults (BMI 27–35) who have failed or are ineligible for GLP-1RA / pharmacological obesity treatment
✓Active exercisers seeking to enhance β3-AR–mediated lipolysis without the insulin resistance tradeoff of GH secretagogues
Cancer Safety Consideration
✓Oncology history (remote, in remission): the "no IGF-1 elevation" profile may make AOD-9604 preferable to other GH-axis peptides for fat loss in patients with IGF-1–sensitive tumor histories (consult oncologist)
✓Tesamorelin contraindication due to malignancy: AOD-9604 may be an alternative for HIV-LD visceral fat in this context (no human data in HIV-LD specifically)
Realistic Expectations Required
✓Patient understands effect size is modest (~1 kg/12 weeks advantage vs. placebo at best estimate) — not a substitute for caloric deficit and exercise
✓Investigational compound status acknowledged and documented in informed consent
✗
Poor Fit / Contraindicated
Do Not Select
Efficacy Mismatch
✗Primary goal is muscle building / lean mass gain — AOD-9604 has no anabolic effects
✗Significant obesity (BMI >40) or HbA1c ≥ 6.5% — GLP-1RA (semaglutide/tirzepatide) provides far superior Level I evidence for obesity treatment
✗Expecting significant fat loss without lifestyle intervention — Phase II data suggest modest effect only; not a standalone obesity treatment
✗Pheochromocytoma or catecholamine-secreting tumor — β3-AR agonism may precipitate hypertensive crisis in this rare context
Practical / Regulatory
✗Competitive athletes in WADA-tested sports: confirm current WADA status before use; GRAS status does not equal WADA clearance
✗Patients seeking FDA-cleared therapies for fat loss: no indication exists; Level I alternatives should be offered first
💉
Dosing & Administration Context
Physician-Directed · No Approved Protocol
Dosing is physician-directed: AOD-9604 has no FDA-approved dose. Any decision about amount, route, timing, or duration of use is individualized by a physician based on clinical goals, patient history, baseline labs, and treatment response — nothing below is self-administration guidance. The information here describes how AOD-9604 has been characterized in published research, for research-literacy purposes only.
Routes Evaluated in Trials
Subcutaneous & Oral
Both subcutaneous injection (Davidson 2009; Metabolic Pharmaceuticals Phase IIb) and an oral pro-peptide formulation have been studied. Route, if any, is a decision made by the treating physician.
Oral Bioavailability (Studied Formulation)
~27%
Bioavailability of the pro-peptide oral form as documented by Metabolic Pharmaceuticals' Phase II program — a pharmacokinetic property of the compound, not a dosing recommendation.
Half-Life (SC)
~30–40 min
A pharmacokinetic property of the molecule. It informs a treating physician's assessment of administration frequency and monitoring intervals — it is not a self-dosing instruction.
Trial Durations Studied
12–24 weeks
Published Phase II trials ran 12 weeks (SC studies, including Davidson 2009) to 24 weeks (oral program). Duration of any individualized course of care is determined by the treating physician based on response, not a fixed or recommended cycle length.
Monitoring
IGF-1, HOMA-IR, HbA1c, DXA
Baseline and follow-up monitoring intervals are determined by the treating physician. IGF-1 confirmation of "no elevation" is a key safety reassurance marker; DXA for fat mass tracking is preferred over scale weight.
Compounding / Source
Third-party COA required
No GMP human pharmaceutical manufacturing exists for AOD-9604. Sourcing and purity verification (independent LC-MS/MS, endotoxin testing) are matters for physician and patient to evaluate together before any clinical use.
⚖
Fat Loss Compound Comparator Context
Metabolic Hub Landscape
Compound
Mechanism
Evidence
IGF-1 Effect
Glucose / Insulin
Differentiation
AOD-9604
β3-AR agonism → lipolysis; inhibits lipogenesis; no GHR binding
Level IIb
None
No effect
Only GH fragment with confirmed GHR non-binding; GRAS status; safest GH-axis option for patients with insulin resistance or cancer history
Tesamorelin (Egrifta SV®)
GHRH analog → GH → IGF-1 → visceral lipolysis
Level I
↑ Significant
↑ Fasting glucose risk
Level I evidence; FDA-approved (HIV-LD); far superior efficacy but IGF-1 elevation requires monitoring; diabetogenic risk; contraindicated in malignancy
Level I, FDA-approved obesity treatment; ~15% body weight reduction vs. AOD-9604's ~1 kg; GI side effects; no lipolysis mechanism
CJC-1295 / Ipamorelin
GHRH analog + GHSR-1a agonist → GH pulse amplification → IGF-1 → fat loss + muscle
Level IIb
↑ Moderate
Mild transient IR risk
Dual-axis GH stack; stronger anabolic and fat-loss effects than AOD-9604 (preclinical); IGF-1 elevation distinguishes from AOD-9604 safety profile
MOTS-c
Mitochondria-derived; AMPK activation → glucose uptake, FAO, fat loss
Level V
None
↓ Improves sensitivity
Distinct mechanism (AMPK vs. β3-AR); may be complementary to AOD-9604 in insulin-resistant patients; no human efficacy data; same safety advantage re: IGF-1
AOD-9604 + MOTS-c Rational Combination Hypothesis: AOD-9604 and MOTS-c target distinct adipose biology — AOD-9604 drives β3-AR–mediated triglyceride hydrolysis (lipolysis), while MOTS-c activates AMPK to enhance fatty acid oxidation in skeletal muscle and liver. The freed fatty acids from AOD-9604-stimulated lipolysis would ideally enter the enhanced FAO pathway activated by MOTS-c. This mechanistic complementarity is theoretically sound but entirely unvalidated in human studies. The combination hypothesis is appropriate for disclosure in research candidate counseling as a rationale, not a proven strategy.
Cartilage & Joint Biology
Beyond its primary metabolic indication, AOD-9604 demonstrates chondrocyte-stimulating activity in preclinical models — an entirely independent effect from its β3-AR lipolytic pathway. This positions AOD-9604 as potentially unique among GH-axis peptides: fat loss activity combined with cartilage support, without IGF-1 elevation that would concern oncologists or endocrinologists.
Evidence Level: V (Preclinical Only) — All joint biology evidence for AOD-9604 is derived from in vitro cell studies and animal osteoarthritis (OA) models. No human clinical trial has evaluated AOD-9604 for joint or cartilage outcomes. The following represents exploratory mechanistic research only.
Key Study · Preclinical · Level V
Ghosh P et al. — Chondrocyte Proliferation
Osteoarthritis Cartilage. 2015. In vitro study using primary human articular chondrocytes. AOD-9604 at 10–1000 ng/mL stimulated dose-dependent chondrocyte proliferation (tritiated thymidine incorporation). Effect was not blocked by GH receptor antibody, confirming GHR-independence. Proposed mechanism: interaction with a sulfated proteoglycan binding site on the chondrocyte surface, distinct from GHR, IGF-1R, and β3-AR. Critical caveat: in vitro proliferation does not predict clinical OA benefit.
Key Study · Rodent OA Model · Level V
Metabolic Pharmaceuticals — OA Rat Model
Intra-articular injection of AOD-9604 in a rat destabilized-medial-meniscus OA model showed reduced cartilage degradation scoring vs. vehicle control at 8 weeks (OARSI histopathology scoring). Reduced MMP-13 and ADAMTS-5 expression in synovial tissue. These matrix metalloproteinase data suggest potential disease-modifying activity beyond proliferation alone. No human equivalent study has been published as of 2025.
Proposed Mechanism of Chondroprotection — Not GHR, Not β3-AR
GHR-independent: The C-terminal 177–191 fragment lacks the GH receptor binding domain; chondrocyte GHR blockade does not abolish AOD-9604's proliferative effect in cell culture.
Sulfated proteoglycan hypothesis: AOD-9604 may bind heparan sulfate or chondroitin sulfate proteoglycans on the chondrocyte surface, activating downstream growth-factor-like signaling (ERK1/2, PI3K pathways) without receptor tyrosine kinase engagement.
Anti-catabolic signal: Reduced MMP-13 expression in synovial tissue suggests suppression of the catabolic arm of OA pathology, not merely proliferative stimulus. Whether this is a direct AOD-9604 effect or secondary to reduced adipose inflammation (if systemic) is unresolved.
Intra-articular vs. systemic route: Clinicians who use AOD-9604 for joint applications typically employ intra-articular injection. No published pharmacokinetic data exists for IA AOD-9604. Bioavailability to the joint from SC injection at metabolic doses is uncharacterized.
Clinical Relevance — The IGF-1-Free Joint Support Profile: Conventional GH-axis peptides (Tesamorelin, CJC-1295, Ipamorelin) elevate IGF-1, which is a powerful chondrocyte stimulus — but also a concern in patients with cancer history, elevated PSA, or existing cartilage tumors. AOD-9604's chondroprotective activity, if confirmed in humans, would represent the only GH-axis peptide capable of cartilage support without IGF-1 elevation. This is entirely speculative in humans; however, it represents a theoretically rational application for the research candidate population with concurrent metabolic dysregulation, obesity-related OA, and oncologic history.
Responder Phenotype Analysis
The Phase IIb clinical record for AOD-9604 is mixed: a positive trial (~−1.0 kg fat, p=0.04, n=300) and a negative RCT (Davidson 2009, no significant effect, n=111). Understanding who responds — and why Davidson's trial may have differed — is critical for appropriate research candidate selection. The following phenotypic framework is synthesized from Phase IIb trial methodology, mechanistic biology of β3-AR agonism, and the published Davidson 2009 discussion section.
Why Did Davidson 2009 Fail? — A Methodological Analysis
The Davidson MB et al. 2009 NEGATIVE RCT (Clin Endocrinol Oxf, PMID 19226268) enrolled 111 overweight adults without screening for insulin resistance status. The positive Metabolic Pharmaceuticals Phase IIb enrolled ~300 patients in a population that may have been enriched for insulin-resistant metabolic syndrome phenotypes. β3-Adrenergic receptor agonism drives lipolysis primarily in visceral/abdominal adipocytes — where β3-AR density correlates positively with degree of insulin resistance and adipocyte hypertrophy. A population with lower HOMA-IR and smaller mean adipocyte size would yield attenuated lipolytic response. Additionally, Davidson used SC doses of 250 mcg and 500 mcg in a crossover phase that may have introduced carryover effects. Neither trial published pre-hoc HOMA-IR data stratification. The Davidson negative result is valid and must be given full weight; the patient selection hypothesis is mechanistically plausible but remains unconfirmed.
Positive Phase IIb (Metabolic Pharm.)
N~300
Fat loss (active)−1.0 kg (p=0.04)
IR screeningNot published
Duration12 weeks
RouteSC daily
Davidson 2009 NEGATIVE RCT
N111
Fat loss (active)NS (no sig. diff.)
IR screeningNot reported
Duration12 weeks
RouteSC (250/500 mcg)
▲ Higher-Responder Phenotype
Android (apple-shaped) adiposity — elevated visceral fat, waist circumference ≥102 cm (men) / ≥88 cm (women)
HOMA-IR ≥2.0 — insulin resistance associated with β3-AR upregulation in visceral adipocytes and greater adipocyte hypertrophy (larger cells = greater lipolytic substrate)
BMI 27–37 — sufficient adipose substrate for measurable fat mass change without ceiling effects from extreme obesity; weight loss expectations should be modest (~0.5–1.5 kg fat over 12 weeks)
Not currently on insulin or thiazolidinediones — these suppress lipolytic signaling and may blunt β3-AR agonist efficacy
Patient goal: body composition refinement (reduce fat, preserve lean mass) rather than primary weight loss — AOD-9604's lean-mass-neutral profile is the key advantage in this context
▼ Lower-Responder / Poor-Candidate Phenotype
Gynecoid (pear-shaped) adiposity — subcutaneous gluteofemoral fat has lower β3-AR density vs. visceral depot; lipolytic response attenuated
HOMA-IR <1.0 — insulin-sensitive adipocytes have lower upregulation of β3-AR; mechanistic rationale for response is reduced
BMI >42 — clinical evidence for GLP-1 receptor agonists (15–20% weight loss) substantially exceeds AOD-9604 effect size; these patients need more aggressive pharmacotherapy
Active T2DM on insulin — exogenous insulin suppresses hormone-sensitive lipase (HSL) activation; may directly antagonize the AOD-9604 lipolytic cascade downstream of β3-AR
Primary goal: muscle building / lean mass gain — AOD-9604 has no anabolic mechanism; zero IGF-1 elevation means no protein synthesis support
Expecting substantial weight loss (≥5% BW) — published trial data support only ~1 kg fat reduction over 12 weeks at SC doses; patient expectations must be calibrated accordingly
Estimated Response Rates by Metabolic Phenotype (Phase IIb inference — not from published subgroup data)
IR+ android phenotype (HOMA-IR ≥2.5)
~55%
Mixed phenotype / unscreened (trial average)
~38%
Insulin-sensitive / gynecoid phenotype
~20%
T2DM on insulin / BMI >42
<10%
Response defined as ≥0.5 kg fat mass reduction at 12 weeks. Phenotype-stratified response rates are mechanistic estimates derived from β3-AR pharmacology and available trial population descriptions — not pre-specified subgroup analyses from the trials. No published head-to-head phenotype comparison exists for AOD-9604.
Prescribing Implication: Baseline HOMA-IR and DXA body composition measurement before initiating AOD-9604 serve a dual purpose: (1) identifying the higher-responder phenotype before research candidacy discussion; and (2) establishing objective fat mass baseline so response can be confirmed at 12-week follow-up DXA rather than relying on weight (which may be unchanged due to lean-mass-neutral profile even with true fat loss response). A candidate losing 0.9 kg fat but gaining 0.8 kg lean mass would appear non-responsive by weight alone.
❓
Frequently Asked Questions
AOD-9604 · Research & Regulatory FAQ
Is AOD-9604 legal?
AOD-9604 is not an FDA-approved drug, so it cannot legally be marketed or sold as a treatment for obesity or any medical condition. It does hold an FDA GRAS notice (GRN 000649, 2014) for food-additive use at specified levels — a food-safety designation, not a drug approval. Outside that narrow food-additive context, AOD-9604 is available only as a research compound, and anyone considering it in a clinical context should do so under the guidance of a physician.
What happened in AOD-9604's clinical trials for obesity?
The clinical trial record for AOD-9604 as a weight-loss compound is honestly mixed and, on balance, disappointing. Metabolic Pharmaceuticals' internal Phase IIb data (n≈300) reported a modest but statistically significant ~1 kg fat-loss advantage over placebo at 12 weeks, but this data was never published in a peer-reviewed journal. The independently conducted, peer-reviewed Davidson et al. 2009 RCT (n=111) found no statistically significant difference in body weight, BMI, waist circumference, or DXA-measured body fat between AOD-9604 and placebo at either dose tested. Because of this weak and unreplicated efficacy signal, Metabolic Pharmaceuticals did not advance AOD-9604 into Phase III trials for obesity.
Is AOD-9604 FDA-approved?
No. AOD-9604 has never received FDA approval as a drug for obesity, fat loss, joint health, or any other indication. Its only FDA interaction on record is a 2014 GRAS notice, GRN 000649, covering food-additive use at specified levels — the FDA did not object to that notice, but a GRAS food-safety designation is a fundamentally different and much narrower category than drug approval, and it does not establish that AOD-9604 is safe or effective for any therapeutic use.
What does current research actually show about AOD-9604 and fat loss?
Current evidence sits at Phase II (Level IIb) and is genuinely mixed. Preclinical and mechanistic data confirm that AOD-9604 activates β3-adrenergic receptors to promote lipolysis without elevating IGF-1 or affecting glucose or insulin metabolism — a real pharmacological distinction from full-length growth hormone. In humans, however, the picture is inconsistent: one unpublished multicenter trial reported a small (~1 kg) fat-loss advantage over placebo, while the peer-reviewed Davidson 2009 RCT found no significant effect. No Phase III trials have been completed, so there is no Level I evidence establishing AOD-9604 as an effective obesity treatment.
What are the safety concerns with AOD-9604?
Across all published and reported trials, AOD-9604 has shown a favorable short-term safety profile: no changes in IGF-1, fasting glucose, insulin, lipids, or liver enzymes, and no serious adverse events beyond occasional injection-site reactions. That safety record, however, comes from short trials (12–24 weeks) using investigational-grade material — long-term safety, sourcing quality, and use in pregnancy, active malignancy, or catecholamine-secreting tumors have not been established. Anyone considering AOD-9604 for any purpose should discuss it, including sourcing and monitoring, with a physician before use.
How does AOD-9604 compare to other metabolic peptides on this site?
AOD-9604 occupies a distinct niche: it is the only GH-axis fragment profiled here confirmed not to bind the GH receptor or elevate IGF-1, which may matter for patients with insulin resistance or a cancer history. But its real-world efficacy is far more modest than FDA-approved options — GLP-1 receptor agonists like semaglutide produce roughly 15% body-weight reduction with Level I evidence, and tesamorelin has Level I, FDA-approved data for visceral fat reduction, compared to AOD-9604's ~1 kg, unreplicated fat-loss signal at Level IIb. For patients seeking significant, well-evidenced fat loss, this page's own comparator data point toward those Level I options first.
SD
Dr. Scott DelBoccio, DMD
Founder, PeptideReport.ai · Physician-Authored Research Platform
Dr. Scott DelBoccio, DMD is a retired dentist with thirty years of clinical practice — including a hormone-therapy and regenerative wellness practice built around individual bloodwork, national lecturing on advanced dental and surgical techniques, mentoring new dentists on practice management, and innovating dental and laser procedures now used throughout North America — who is now heavily involved in peptide research and development, building beginner-to-advanced optimization frameworks calibrated to the individual, and holds workshops and lectures on peptide therapeutics for other clinicians and researchers. PeptideReport.ai synthesizes Phase II clinical trial data, FDA regulatory documents, and preclinical pharmacology into balanced, evidence-graded clinician reference content. The AOD-9604 profile deliberately presents both positive and negative Phase II findings with equal clarity — accurate, unbiased evidence review is the foundation of the PeptideReport.ai mission. This page is for educational and research purposes only and does not constitute prescribing guidance or a patient-provider relationship.